According to the latest report by IMARC Group, titled, “Anticoagulants Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027“, The global anticoagulants market size reached a value of US$ 34.0 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 60.8 Billion by 2027, exhibiting a CAGR of 10.2% during 2022-2027.
Anticoagulants are specialized medicines that prevent blood clots and reduce the chances of developing severe medical conditions, such as strokes and heart attacks. They include warfarin, apixaban (eliquis), dabigatran (pradaxa), edoxaban (lixiana), and rivaroxaban (xarelto). They are widely used in the treatment of transient ischaemic attacks, atrial fibrillation and heart attacks, deep vein thrombosis (DVT), stroke, and pulmonary embolisms (PE). They aid in thinning blood and preventing blood cells called platelets from clumping together to form a clot and prolonging the clotting time. They come in different strengths and colors and are usually available in oral, such as tablets and capsules, and injectable forms. At present, anticoagulants are readily available at online stores, hospitals, and retail pharmacies across the globe.
Note: We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Get a PDF Sample for more detailed market insights: https://www.imarcgroup.com/anticoagulants-market/requestsample
Anticoagulants Market Trends and Drivers:
The growing geriatric population and the increasing prevalence of cardiovascular disorders across the globe represent one of the key factors positively influencing the market. In addition, rising cases of pulmonary embolism (PE) on account of sedentary lifestyles and hectic work schedules are increasing the risk of heart-related diseases worldwide. This, along with the extended sitting, smoking, trauma, blood disorders, and autoimmune diseases can cause blood clotting in different parts of the body, which is catalyzing the demand for anticoagulants. The increasing prevalence of human immunodeficiency virus (HIV), Lyme disease, obesity, hepatitis C, and chronic inflammation are creating a favorable market outlook. Moreover, the increasing awareness about weight management and maintaining cardiovascular health among individuals and the importance of blood thinning is bolstering the market growth. Additionally, the easy availability of anticoagulants across offline and online distribution channels, coupled with the facilities of free doorstep delivery, lucrative deals and discounts, and secured payment gateways, are propelling the market growth. Besides this, the introduction of new anticoagulant agents that are orally administered and need less laboratory monitoring is contributing to the market growth. Furthermore, increasing investments by leading market players in research and development (R&D) activities for quality improvement of anticoagulants are creating a positive market outlook. Furthermore, favorable initiatives by non-profitable organizations (NPOs) to promote awareness about cardiovascular health are strengthening the growth of the market. Moreover, the growing partnerships between public health agencies and governments of various countries to prevent heart disease and strokes are catalyzing the demand for anticoagulants. Apart from this, the integration of advanced technologies, such as artificial intelligence (AI) on mobile devices for medication adherence in stroke patients undergoing anticoagulation therapy, is anticipated to drive the market.
Anticoagulants Market 2022-2027 Competitive Analysis and Segmentation:
The competitive landscape of the industry has also been examined along with the profiles of the key players.
- Alexion Pharmaceuticals Inc
- Aspen Holdings
- Bayer AG
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Daiichi Sankyo Company Limited
- Reddy’s Laboratories Ltd
- GlaxoSmithKline plc
- Johnson & Johnson Private Limited
- Pfizer Inc.
The report has segmented the market based on drug class, route of administration, distribution channel and application.
Breakup by Drug Class:
- Novel Oral Anticoagulants (NOACs)
- Heparin and Low Molecular Weight Heparin (LMWH)
- Vitamin K Antagonist
Breakup by Route of Administration:
- Oral Anticoagulant
- Injectable Anticoagulant
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Stores
Breakup by Application:
- Atrial Fibrillation and Heart Attack
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism (PE)
Breakup by Region:
- North America
- Latin America
- Middle East and Africa
Ask Customization and Browse full report with TOC & List of Figure: https://www.imarcgroup.com/anticoagulants-market
Note: We are updating our reports, if you want the report with the latest primary and secondary data (2023-2028) including industry trends, market size and competitive landscape, etc. click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours.
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
Americas: – +1 631 791 1145 | Africa and Europe: – +44-702-409-7331 | Asia: +91-120-433-0800